All Industries

Cboe Is Helping Lead The Retail Trading Revolution With A New Robinhood Collaboration

Benzinga

By Johnny Rice, Benzinga Henry Schwartz, Global Head of Client Engagement, Data and Access Solutions for Cboe Global Markets Inc. (Cboe: CBOE), was interviewed by Benzinga at the HOOD Summit, presented by Robinhood (NASDAQ: HOOD). Cboe Global Markets is the world’s leading derivatives and securities exchange network – operating in 27 markets globally – and facilitates trading in options, futures, equities, FX and more for all investors. The company has long been an innovator in financial products. Mr. Schwartz discussed the revolutionary growth of the retail market and how Cboe is helping drive that growth. He also spoke of the exciting collaboration with Robinhood. Watch the full interview here: Featured photo by Jason Briscoe on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 18, 2024 08:55 AM Eastern Standard Time

Video Image

News Release

OYO enters commitment with Deutsche for a loan facility

Oravel Stays Limited

Oravel Stays Limited, which operates the global travel technology brand OYO has entered into a commitment letter with Deutsche Bank AG New York Branch (“DBNY”) and Deutsche Bank Securities Inc. As a part of the arrangement, DBNY has provided the Company with a commitment for a new term loan facility to finance OYO’s recently announced acquisition of G6 Hospitality (G6). OYO recently announced its acquisition of G6 Hospitality, the leading economy lodging franchisor and parent company of the iconic Motel 6 and Studio 6 brands, from Blackstone. Earlier in this year OYO reported its first-ever profit after tax (PAT) of ~₹17 million, according to the company's annual report. The company also reported eight consecutive quarters of positive Adjusted EBITDA. OYO's Adjusted EBITDA grew by 215% to reach ~$105 million in FY 23-24, up from ~$33 million in FY 22-23. The company had also concluded an equity funding round of $175 million was led by the company's founder Ritesh Agarwal and included participation from various Indian family offices and private investors including InCred Wealth, J&A Partners, renowned investor Ashish Kacholia the family office of Mankind Pharma promoters and ASK Financial Holdings. Original article published in Tech Observer by Mohd Ujaley. Click to read in detail https://techobserver.in/news/startups/oyo-secures-deutsche-bank-loan-commitment-to-fund-g6-hospitality-acquisition-288914/ About Tech Observer Tech Observer is a premium monthly technology news magazine published from New Delhi that brings a critical perspective and analysis from a wide spectrum of government technology, enterprise IT, startups, telecom and consumer electronics. The magazine focuses on all aspects of technology usage in government organizations, public sector and enterprises, with special emphasis on the role of influencers such as senior government officials, CIOs, CTOs, CISOs and IT heads. Contact Details Tech Observer Md Ujaley, Editor, Tech Observer +1 931-358-3248 editor@techobserver.in Company Website https://www.techobserver.in

November 18, 2024 08:45 AM Eastern Standard Time

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market

Benzinga

By Meg Flippin, Benzinga From alleviating lower back pain to treating obesity, stem cells can play a central role in healing some of the world’s most prevalent conditions. For good reason: stem cells are regenerative and can turbocharge the body's natural healing process. BioRestorative Therapies, Inc. (NASDAQ: BRTX), a regenerative medicine company focused on stem cell-based therapies and products, has been inkling deals and securing patents to treat back pain and obesity as well as other hard-to-cure ailments and diseases. Take BRTX-100 for example. It’s BioRestorative’s autologous stem cell product for chronic lower back pain. It uses a patient’s stem cells, which are harvested, cultured and then injected directly into the affected disc to start the repair process. BRTX-100 is designed to treat the 25 million people in the U.S. who suffer from chronic lower back pain each year, half of whom have or will be diagnosed with disc degeneration, reports the company, and current treatments on the market are less than ideal. Opioid pain relievers, steroid injections and physical therapy help manage pain but don’t cure it. Surgery is another option, but clinical outcomes can be limited. Phase 2 Trial Results Coming The company is currently engaged in a phase 2 clinical trial using BRTX-100 to treat persistent lower back pain caused by painful degenerative discs. This week (Nov. 10-14), BioRestorative presented new preliminary 26–52-week blinded data from the ongoing phase 2 clinical trial at the Orthopaedic Research Society (ORS) Philadelphia Spine Research Society (PSRS) 7th International Spine Research Symposium in Skytop, Pennsylvania. BioRestorative will also make the data available through a public announcement. “In February 2024, we were strongly encouraged that the Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at 26 and 52 weeks after injection indicated a positive trend compared to the baseline with the first four patients enrolled in the study,” said BioRestorative’s CEO Lance Alstodt. “Now, at ORS PSRS 2024, we have revealed data on 10 patients. Blinded preliminary clinical data of safety and efficacy endpoints are very encouraging, with patient reported pain and function outcomes demonstrating a positive trend,” said Mr. Alstodt. “Most importantly, at 26 weeks, 70% of the patients are reporting a significantly greater than 30% increase in function and a more than 30% decrease in pain. If data continues with this trend, we are confident that we will hit our efficacy end points for the phase 2 trial,” he continued Fighting Obesity With Stem Cells With A Focus On Growing IP Portfolio Then there is BioRestorative’s ThermoStem, which uses brown adipose-derived (brown fat) stem cells to generate new brown fat tissue to target obesity and metabolic disorders. This type of fat is known to burn rather than store energy. Elevated levels of brown fat have been shown to increase metabolism and facilitate weight loss, reports BioRestorative. It’s a big market for BioRestorative to go after. After all, 40% of Americans are obese; 30% have type 2 diabetes or pre-diabetes and half of Americans have at least one major risk factor for heart disease, according to data compiled by the company. ThermoStem is also making news with BioRestorative recently announcing that the Israel Patent Office has issued the company a Notice of Allowance for a new patent application (Israeli Patent Appl. No. 287557) covering several fundamental aspects of its allogeneic, off-the-shelf ThermoStem platform. It's the 14th international patent and covers non-naturally occurring three-dimensional brown adipose-derived stem cell (BADSC) aggregates, encapsulation, a method for making them and a method for treating a patient with a disorder. “We believe that our ThermoStem-based BADSCs hold tremendous promise to deliver a superior efficacy and tolerability profile over GLP-1 drugs,” said Alstodt. “This latest patent issuance demonstrates our strong commitment to protecting the innovation of our ThermoStem program and the significant potential commercial opportunity that it represents for ourselves and any current and/or future potential licensing partners. And, given Israel’s global prominence in stem cell research, we are particularly excited by this latest patent issuance.” Expanding Via Licensing In addition to securing patents and gearing up to present clinical data, BioRestorative recently obtained a license from the New York State Department of Health (NYSDOH) to process, isolate, expand and preserve allogeneic (non-autologous) donor tissue, including stem cells, for medical research. In New York, companies are required to have a license to engage in tissue and stem cell activities. Previously BioRestorative was licensed by the NYSDOH to act as a tissue bank for the processing of mesenchymal stem cells derived from autologous donors only. BioRestorative says the expanded license enables it to leverage its state-of-the-art cGMP manufacturing to process, bank and distribute clinical-grade allogeneic (off-the-shelf) biologics. “It will significantly enhance our ability to develop an unrivaled clinical pipeline of off-the-shelf cell-based biologic products,” says Alstodt. Stem cells play an important role in treating several prevalent diseases. The remedies of today aren’t cutting it. BioRestorative aims to change that with BRTX-100 and ThermoStem – and it’s working hard to get the licenses and patents to make that happen. Other companies competing in the cell-based biologics or chronic pain treatment space include Mesoblast ( NASDAQ: MESO), Brainstorm Cell Therapeutic (NASDAQ: BCLI) and Longeveron (NASDAQ: LGVN). To learn more about BioRestorative’s stem cell therapies, click here. Featured photo by Sasun Bughdaryan on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 18, 2024 08:45 AM Eastern Standard Time

Image

The Crossroads Summit 2024 Is Just Days Away – Get Your Tickets Now To Gain Insights About A Changing World From Renowned Minds

Benzinga

By Josh Enomoto, Benzinga While all eyes may be on the election of former President Donald Trump to a second non-consecutive term, that’s just one of the critical catalysts that stand poised to potentially forever change the investment landscape. That’s why there’s not a moment to miss, and concerned market participants may want to attend the upcoming Crossroads Summit 2024 to prepare for the future. Held in beautiful Miami, FL, Crossroads will bring together some of the brightest minds across finance, applied science and geopolitics. Between Nov. 21 and Nov. 22, renowned experts will share their blueprint for a global ecosystem undergoing radical transitions. Thanks to the rapid social integration of advanced technologies such as artificial intelligence and machine learning, the economy will likely separate investors into two categories: the prepared and everyone else. With only days left for the conference, prospective attendees should make their decision quickly. Following a breakfast and welcoming session by host Karl Sprague and keynote speaker John Bartleman of TradeStation – the title sponsor of the summit — the expert panel will jump right into the thick of things. Given the dynamic environment that’s likely to evolve rapidly, interested investors have little time to waste. Positioning America In A Shifting World Order Right off the bat, Crossroads Summit 2024 kicks off on day one with Peter Zeihan, one of the foremost figures in the field of geopolitical analysis. In his keynote address, “Navigating the End of the World: Geopolitics and the Future of America,” Zeihan offers timely and critical insight into how significant evolutions in global power structures are changing the landscape for U.S. investors. Most notably, Russia’s ongoing invasion of Ukraine represents one of the most dangerous flashpoints in world affairs. In addition, Americans must take note of brewing tensions in China and how these and other factors could impact markets both domestically and abroad. With his inimitable wit and dry humor, Zeihan will provide investors with nuanced context to help investors properly map their decisions. Bracing For Potentially Radical Change In Domestic Policy On the eve of the 2024 presidential election, Vice President Kamala Harris appeared to command the polling advantage. However, when the actual ballots were submitted, President-elect Trump successfully completed a surprising comeback. Subsequently, the opposing Democrats launched into a blame game, but a loss may have been inevitable. Globally, other incumbent political parties suffered defeats amid a populist backlash, as well. This backdrop presents rich grounds for the next panel of industry experts, including Michael Khouw from CNBC, Mike McGlone from Bloomberg, and Katheryn Rooney Vera from StoneX. Saif Ishoof will moderate the discussion, titled “Strategic Adaptation: Preparing for Turbulence in the U.S. Landscape,” which will shine a light on the uncertainties of domestic policy shifts under a second Trump term and how investors may navigate them. Preparing For A Possible Inflection Point With the stratospheric rise of both equities and cryptocurrencies in the post-pandemic cycle, it’s easy to get lulled into a sense of complacency. However, author Neil Howe – an expert on generational cycles – will argue in his discussion “The Fourth Turning: Navigating Crisis and Renewal” that investors need to be more vigilant about contemporary events. Essentially, the good times might not continue unabated. According to Howe’s theory, major historical events are tied to recurring cycles, with each ebb and flow potentially lasting decades. Therefore, while the present bullish framework in global capital markets may entice an acquisitive posture, it’s vital to consider past crises and periods of renewal to properly understand the current juncture. Potential blind spots may include the rise of China and the Biden administration’s subsequent crackdown on the nation’s tech industry. Following a lunch break, moderator Bryan Gorrita will guide a panel of distinguished figures: Mike Green from Simplify Asset Management, Susan Lindeque, founder and CEO of Avestix Group and Luke Gromen of Forest for the Trees. Together, the experts will discuss methods of profiting from the potential turbulence and volatility catapulted by the upcoming “Fourth Turning.” Battening Down The Hatches In one of the most anticipated keynote addresses, economist and author Alan Beaulieu will discuss the potential for a radical paradigm shift that may erupt in the 2030s decade. As co-author of Prosperity in the Age of Decline, Beaulieu adopts a futurist mentality, offering practical and insightful guidance on boosting profits irrespective of business cycle changes. However, because of the nature of contemporary global markets, the expert anticipates a sobering scenario over the next few years. His discussion, “Forecasting the Future: Economic Collapse in the 2030s,” offers a much-needed blueprint on the conditions that could lead to ruin – and most importantly, what investors can do right now to protect their wealth. If there were just one reason to attend the Crossroads Summit 2024, this talking point may very well be it. The Age Of The Machines Finally, conference attendees will gain greater appreciation and knowledge of perhaps the most transformative digital innovation since the rise of the internet: AI and its capacity to positively disrupt multiple sectors, including finance, healthcare and manufacturing. Driving this discussion will be Michael Jabbour, Chief Innovation Officer at Microsoft (NASDAQ: MSFT). Among the foremost leaders in integrating the broader digital transformation, Jabbour specializes in the acceleration and personalization of learning. In addition, his role at Microsoft enables him to empower both educators and students with knowledge about the transformative and ethical application of AI. Through his address, investors can learn firsthand how AI can improve efficiency and, therefore, the bottom line. With multiple enterprises aligned with the generative AI ecosystem racing toward a $4 trillion valuation, this is a discussion investors can’t afford to miss. The Must-Watch Event Of The Year Is Coming Soon With global instability, economic uncertainty and technological disruption defining the landscape of the new economy, Crossroads Summit 2024 kicks off with a key opportunity for investors to learn strategies to navigate uncertainty. From understanding the future of geopolitics to preparing for the next potential economic collapse, the insights shared at this event are more relevant than ever. Investors who attend will be equipped with the knowledge and strategies needed to navigate the complexities of the evolving paradigm. Don’t miss out on this chance to hear from industry leaders and innovators who are shaping the future. Right from the first day, Crossroads is set to offer the guidance and foresight that investors need to thrive in the years to come. Grab your tickets for the 2024 Crossroads Summit and learn how some of America’s most renowned thought leaders are making order out of chaos by clicking here! Featured photo by PIRO by Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 18, 2024 08:35 AM Eastern Standard Time

Image

Direxion Appoints Douglas Yones as Chief Executive Officer

Direxion

Direxion, a leading provider of leveraged, inverse, and non-traditional ETFs, today announced it has appointed Douglas Yones to the position of Chief Executive Officer. In this new role, Yones will lead and drive the strategic vision and growth plan of the firm. Mr. Yones most recently served as Head of Exchange Traded Products at the New York Stock Exchange, overseeing listings and operations for ETPs, Closed-End Funds, and SPACs. His team supported issuers in product development, regulatory compliance, and listing processes to drive growth, distribution, and market quality. “Doug’s history of delivering innovative ideas and valuable insights in the capital markets was a major reason for bringing him aboard, and Direxion is delighted to welcome him to the team,” said Michael Rafferty, CEO of Rafferty Holdings, Direxion’s parent company. “Douglas will help us build on the momentum we’ve created over the past two decades as we continue to provide the high-quality fund solutions our customers have come to expect from us.” Yones is well known and respected in the global ETF industry: Doug spent 17 years at The Vanguard Group, leading Domestic Equity Indexing/ETF Product Management and contributing to ETF development across the U.S., U.K., Canada, and Asia. He holds a ChFC and CETF, an M.B.A. from Villanova, a bachelor’s from Penn State, and is a registered Options and General Securities Principal with FINRA. “Direxion has always set the bar high for progressive ETF ideas—especially in the non-traditional, leveraged, and inverse space,” said Yones. “I couldn’t be more excited to join forces with such a talented team of people. Their dedication and creativity have been instrumental in driving success, and together, we’re ready to bring fresh ideas to life, ensuring that traders and investors continue to receive the unique opportunities they’ve come to expect from us." Yones will be based out of Direxion’s New York City office. About Direxion: Direxion equips investors who are driven by conviction with ETF solutions built for purpose and fine-tuned for precision. These solutions are available for a broad spectrum of investors, whether executing short-term tactical trades, or investing in thematic strategies. Direxion’s reputation is founded on developing products that precisely express market perspectives and allow investors to manage their risk exposure. Founded in 1997, the company has approximately $48.5 billion in assets under management as of September 30, 2024. For more information, please visit www.direxion.com. There is no guarantee that the Funds will achieve their investment objectives. For more information on all Direxion Shares ETFs, go to www.direxion.com, or call us at 866.301.9214. Leveraged and Inverse ETFs pursue daily leveraged investment objectives which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying index over periods longer than one day. They are not suitable for all investors and should be utilized only by sophisticated investors who understand leverage risk and who actively manage their investments. An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. A Fund’s prospectus and summary prospectus should be read carefully before investing. ALPS Distributors, Inc. Contact Details Ditto Public Relations Danielle Black, AD direxion@dittopr.co Company Website https://www.direxion.com/

November 18, 2024 08:30 AM Eastern Standard Time

Image

Are Trust Deeds A More Secure Alternative To Real Estate Syndicates?

Benzinga

By James Blacker, Benzinga For investors seeking a more secure and reliable alternative to real estate syndication, trust deeds may potentially offer a flexible and low-risk investment with the promise of high returns, but without the hassle of property management. A trust deed is an agreement between a borrower and a lender to have a private loan secured by real estate. Trust deed investors act as the bank, earning passive income through interest rate payments. This type of investment is facilitated by a mortgage broker and loan servicing agent, such as Ignite Funding. Benefits Of Trust Deed Investing Over Syndication Trust deeds are an often-overlooked investment opportunity, despite the many advantages they have over real estate syndicates. One of the key benefits is the higher level of security they offer. While syndication involves pooling funds to purchase and collectively manage properties, trust deed investors hold a secured interest in a specific property, which limits risk as they have the right to foreclose if the borrower defaults on the loan. Furthermore, in the case of “first” trust deeds, the deed holder is the first to get paid back in the event of a default, giving investors an added layer of security. There is also a greater degree of transparency when opting for trust deed investments over syndications, as investors are able to conduct thorough due diligence on the underlying property. This transparency, along with fixed interest rates and regular monthly payments, helps ensure a stable and reliable income stream, making it an attractive option for anyone looking to diversify their investment portfolio. Trust deed investors also have more control, as they can choose specific properties to invest in and therefore tailor their own real estate investment strategy. They also have more flexibility as they can choose the loan and terms that suit their objectives. This type of control and adaptability is not something you typically get with syndication. Additionally, by earning interest on the loan amount, trust deeds often yield higher returns, and can potentially be more profitable than traditional syndications and other passive investments. How To Maximize Returns With Trust Deeds To optimize returns, it is important to choose a reputable mortgage broker with a strong track record. Partnering with a reliable company such as Ignite Funding can boost your chances of reaping a high return on investment. They can help you carry out due diligence on both the property and borrower, which is a crucial step in trust deed investment. Prudent investors will also diversify their investments across multiple properties or loan types in order to mitigate risk. This can help protect their investments against market fluctuations and balance potential returns with effective risk management. If you're looking for an investment that combines security, transparency and flexibility with the potential for strong returns, trust deeds are an option worth exploring and may offer a compelling alternative to real estate syndications. Find out more about trust deed investing by visiting the Ignite Funding website or text the word "Benzinga" to 702-919-4281 for additional information. Ignite Funding, LLC | 6700 Via Austi Parkway, Suite 300, Las Vegas, NV 89119 | P 702.739.9053 | T 702.919.4281 | F 702.922.6700 | NVMBL #311 | AZ CMB-0932150 | | Money invested through a mortgage broker is not guaranteed to earn any interest and is not insured. Prior to investing, investors must be provided applicable disclosure documents. Featured photo by Oleksandr Pidvalnyi from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 18, 2024 08:30 AM Eastern Standard Time

Image

BitFuFu Posts Double-Digit Third Quarter Revenue Growth In A Challenging Market

Benzinga

By Meg Flippin, Benzinga What sets BitFuFu apart from its peers – such as Riot Platforms Inc (NASDAQ: RIOT), BitDeer (NASDAQ: BTDR) and MARA Holdings Inc. (NASDAQ: MARA) – is its unique approach of collaborating with mining partners to boost revenue and drive efficiencies rather than keeping it all in-house. This strategy, combined with its smaller, more focused business model, has positioned BitFuFu as a leader in growth within the industry. For instance, in the second quarter, BitFuFu reported revenue of $129.4 million and net income of $1.3 million. In comparison. Riot Platforms generated $70 million in revenue but reported a net loss of $(0.32) per share, while MARA recorded revenue of $145 million, but suffered a loss of ($0.72) per share. Despite rising costs to mine Bitcoin, BitFuFu (NASDAQ: FUFU), the digital asset mining company based in Singapore, achieved double-digit growth in the third quarter. The company reported revenue of $90.3 million for the third quarter of 2024, a 47.5% increase year-over-year, and achieved adjusted EBITDA of $5.8 million. This quarter marked the first full quarter after the Bitcoin halving event in late April, which reduced the Bitcoin block subsidy from 6.25 to 3.125 Bitcoin per block. BitFuFu (FUFU.US) has also attracted investor interest, highlighted by H.C. Wainwright analyst Kevin Dede’s initiation of coverage with a ‘Buy’ rating and a $7 target price for the stock. “Despite the halving event BitFuFu had another successful quarter generating positive adjusted EBITDA,” said BitFuFu chairman and CEO Leo Lu during a conference call to discuss quarterly results. “I am proud to say that the third quarter of 2024 is the 11th consecutive quarter BitFuFu has generated positive adjusted EBITDA. This consistency demonstrates the profitability and resilience of our business model, regardless of whether the price of Bitcoin is in a bear market or bull market.” Compared to industry peers Riot Platforms (RIOT) and MARA Holdings (MARA), BitFuFU’s market capitalization remains relatively modest. However, BitFuFu stands out for its growth trajectory, even in a challenging market. Between the second quarter of 2023 and 2024, BitFuFu achieved a 69.7% increase in revenue and reported positive net income of $1.3 million. In contrast, MARA posted a net loss of $199 million, and Riot recorded a loss of $84 million over the same period. These results underscore BitFuFu’s growth momentum and demonstrate its ability to outperform key competitors in both profitability and revenue growth within the current market environment. Check out BitFuFu’s third-quarter conference call here! Revenue Growth Driven By Cloud Mining In the third quarter, BitFuFu reported that revenue growth was primarily driven by its cloud mining solutions, which generated $68.9 million in revenue, accounting for 75% of the company’s total quarterly revenue. According to CEO Leo Lu, this growth was fueled by both new customer acquisitions and strong retention among existing customers. Cloud-mining registered users increased by 75.3% to 455,764, up from 259,929 in the year-ago quarter. Revenue from BitFuFu’s self-mining business also rose to $20.5 million, marking a 40.4% year-over-year gain despite an increase in Bitcoin mining costs. During the quarter, the cost per mined Bitcoin rose to $59,452 due to increased blockchain difficulty and the impact of the April halving event. The cost includes electricity, hosting fees, the cost of hash rate purchased from suppliers and the cost of leased mining equipment, which comprises most of BitFuFu’s mining fleet. As a result, Lu noted that the $59,452 figure may not be directly comparable to some peers, as other companies may exclude depreciation of miner costs in their calculations. Expanding Mining Reach and Reducing Costs To offset rising costs and expand its operational footprint, BitFuFu undertook several strategic actions. During and shortly after the third quarter, the company reallocated its mining fleet, secured favorable long-term, lower-cost purchase agreements and leveraged new low-cost electricity sites to enhance operational efficiency. The company shifted both leased and self-owned mining machines from high-cost facilities to lower-cost facilities while retaining the U.S. as a key strategic base for its mining operations. By the end of the third quarter, BitFuFu’s hosting capacity had grown to 556 megawatts (MW) across 17 sites spanning three continents, compared to 339 MW across 16 sites on two continents in the same period last year. Of these sites, ten are in the U.S., six are in Ethiopia and one is in Paraguay. As a result, average hosting costs decreased to 6.8 cents per kilowatt hour, a 13% improvement from the second quarter. In October, BitFuFu further reduced hosting costs by an additional 5% to 6.5 cents per kilowatt hour. “Our ability to quickly adjust to changes in the market is a testament to the advantages of our asset-light strategy, particularly in the challenging period following Bitcoin halving events,” said Lu. Building Energy Platform by Acquiring Mining Infrastructure In October BitFuFu signed a definitive agreement to purchase a majority stake in an 80-megawatt mining site in Ethiopia, with an electricity cost of around 3.6 cents per kilowatt hour. The site, which can deploy 26,000 miners, is currently operating 8,000 AntMiner S19j Pro miners with a combined 0.8 Exa Hash. CEO Lu stated that in the coming quarter, the company plans to fill in the remaining capacity to reach a combined mining capacity of 2.5 EH/s. Longer term, BitFuFu believes the facility could reach 4.6 EH/s when running AntMiner S21 Series miners. The company’s total mining capacity under management increased 88.5% year-over-year in Q3 to 26.2 EH/s, compared to 13.9 EH/s in Q3 last year. “This acquisition not only increases the diversity of our mining portfolio but also aligns with our strategic goal to build a sustainable energy platform,” said Lu. He noted that BitFuFu is also evaluating a pipeline of potential M&A opportunities with over 100 MW in both traditional grid and off-grid options. BitFuFu is actively exploring additional regions with favorable energy rates to further reduce costs and enhance long-term operational stability. Lu stated, “As we continue our journey, we are looking at off-grid and low-cost energy solutions as potential avenues to further stabilize our cost structure and enhance profitability.” Lu continued, “We believe owning some data centers is essential to BitFuFu’s business. We are focusing on finding the optimal mix between a pure asset-light strategy and an asset-heavy strategy.” Looking ahead, Lu emphasized the company’s commitment to growth and shareholder. “With continued investment in stable energy sourcing and capacity growth, we are confident in our ability to deliver resilient performance in the face of a dynamic market environment,” he said. Featured photo by Erling Løken Andersen on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 18, 2024 08:25 AM Eastern Standard Time

Image

TESSAN Announces Major Black Friday and Cyber Monday Discounts on Popular Outlet Extenders

Rev Up Marketers

TESSAN, a leading provider of innovative power solutions, is excited to announce special Black Friday and Cyber Monday promotions on its highly popular outlet extenders. Due to the small size, ease of use, and reliability of TESSAN outlet extenders, they have been conceived to provide the most optimal charging experience possible in an appropriate manner considering the restricted outlet space. With the holiday shopping season just around the corner, TESSAN is providing deep discounts on its most popular outlet extenders, up to 30% off the price of each individual model, e.g. Due to the special, limited-time nature of these, these offers are very likely to sell out quickly and therefore customers are urged to plan before-hand and seek to utilise the special offers. Unbeatable Features for the Modern Home and Office After all, TESSAN outlet extenders are, in fact, flexible and therefore an innocuous means of powering all the way out of the home office to a visit, etc. Key features include: Multiple Outlet Configurations: The majority of models have four AC ports and three USB ports so that the user can charge multiple devices from just one wall socket. Compact and Portable: TESSAN extenders are incredibly lightweight and portable, perfect for frequent travelers and remote workers who need to stay connected on the go. Fast Charging: Using USB power delivery ports, these extenders provide fast charging for a variety of USB-powered devices (mobile phones, tablets, etc. Surge Protection: Off-line surge protection is also included to prevent sudden changes in power, which makes TESSAN extenders a robust solution under any of the considered environments. Sleek Design: Because of the form and the narrow size of the TESSAN extenders, these extenders can be small and placed comfortably, and snugly, inside spaces that are very constricted, without compromising the work of the other plugs. Special Offers: Bundles and Discounts Besides the exclusive discounts from the single product level, TESSAN provides special bundle offers to customers who want to install the practical power solutions in more rooms, or to the people who would like to be equipped with the tools. These bundled packages are such big discounts, which work for a family group, a boardroom meeting, or a thoughtful gift for the holidays. Why Shop TESSAN for Black Friday and Cyber Monday Get the home or office power-up of your dreams with TESSAN’s Black Friday and Cyber Monday deals. Whether you’re looking for an extender for everyday use or a portable travel solution, TESSAN has a model that suits your needs. Don't miss out on these amazing savings that won't be around for long. Tips to Maximize Your Savings To get the best impact of these time-off concessions, as well as consider the following:. Sign Up for Email Alerts: Update by subscribing to TESSAN email alerts with the sale start date and details. Plan: It’s a good idea to review the available models beforehand so that you’ll be prepared to go shopping as soon as the sale starts. Compare Products: TESSAN provides multiple outlet extenders with varying capabilities. Comparatively, the models are chosen to match your requirements. Perfect for Gifting Due to their mininess, lack of expansion, and portability, TESSAN outlet extenders are excellent gifts, particularly for technology lovers and travelers who fly often (e.g. Their practical nature ensures they’ll be appreciated year-round. About TESSAN As a pioneer in power solutions, TESSAN offers a range of premium products with high quality to fulfill charging and power requirements in today's homes and business premises. In keeping with an ethos for innovation, safety, and user experience, TESSAN is constantly embedding solutions so people can stay connected more affordably. Contact Details Tessan Annie Dong +1 833-362-9899 maggie@tessan.com Company Website https://tessan.com/

November 18, 2024 08:12 AM Eastern Standard Time

Image

Impact BioMedical Inc. (NYSEAmerican: IBO): Targeting Chronic Diseases with Patented Breakthroughs

IBO

The biotechnology industry is booming, with a global market valued at $1.55 trillion in 2023 and projected to grow at a 13.96% annual rate through 2030. Driving this growth are government-backed initiatives to modernize regulations, streamline approvals, and improve access to personalized medicine and orphan drugs—paving the way for emerging companies. Chronic inflammatory diseases, identified by the World Health Organization as the leading global health threat, are a key focus area. Recent estimates reveal nearly 60% of Americans live with at least one chronic condition, and three out of five deaths worldwide result from diseases like cancer, diabetes, and respiratory disorders. This urgent need for solutions presents immense opportunities for innovation. In this rapidly evolving landscape, Impact BioMedical Inc. (NYSEAmerican: IBO) emerges as a promising player committed to advancing healthcare innovation. A Promising Player in Biotech Impact BioMedical Inc. (NYSEAmerican: IBO), a pioneering biotechnology firm, has quickly captured attention since its IPO in September 2024. Focused on discovering, developing, and patenting innovative solutions for human healthcare and wellness, the company is building momentum as it positions itself to address unmet medical needs in various fields. A Strong Start: The IPO and Investor Confidence On September 16, 2024, Impact BioMedical entered the public market with its initial public offering of 1.5 million shares priced at $3.00 each. The IPO, which raised $4.5 million, garnered robust interest, with over 30% of shares purchased by existing investors. This strong participation signals significant confidence in the company’s potential and direction. Impact BioMedical CEO Frank D. Heuszel commented on the IPO’s success, emphasizing that investor confidence reflects the belief in the company’s mission to deliver transformative healthcare solutions. Leadership Positioned for Growth At the helm of Impact BioMedical is a highly experienced leadership team. CEO Frank D. Heuszel, with a background in finance and executive leadership, has been instrumental in guiding the company’s strategic direction. Heuszel’s tenure as CEO of DSS, Inc., Impact BioMedical’s parent company, since 2019 has prepared him to navigate the complexities of biotech innovation and commercialization. Supporting Heuszel is COO Mark Suseck, who brings extensive experience in strategy, licensing, and acquisitions from his time at DSS BioHealth Holdings and Vivacitas Oncology. CFO Todd Macko complements the team with his expertise in financial planning, analysis, and mergers and acquisitions, ensuring the company is fiscally sound as it expands. Together, this leadership team aims to drive innovation and establish Impact BioMedical as a key player in the biotechnology sector. Innovative Technology Platforms with Real-World Applications Impact BioMedical is built on a foundation of cutting-edge technologies designed to tackle pressing healthcare challenges. Two standout platforms, 3F and Linebacker, highlight the company’s unique approach to improving human health and wellness. The 3F insect repellent technology recently secured a U.S. patent, showcasing its potential as a natural solution to reduce insect landings and bites. Unlike chemical-based alternatives, 3F uses plant-derived formulations to effectively “blind” insects to human presence. Its applications range from standalone repellents to integrations in shampoos and detergents. With vector-borne diseases accounting for 17% of infectious diseases globally, 3F addresses a significant market need. CEO Frank Heuszel emphasized the company’s commitment to advancing commercialization efforts with potential partners, aiming to provide eco-friendly solutions for outdoor safety. Another major achievement is the Canadian patent for Linebacker technology, which targets inflammatory diseases with novel phenolic compounds. This platform offers potential relief for conditions such as arthritis, asthma, and inflammatory bowel disease, while mitigating the side effects associated with traditional treatments. Derived from myricetin, a plant-based flavonoid, Linebacker compounds are designed to inhibit inflammatory responses and oncogenic pathways. The technology has been licensed to ProPhase Laboratories for global development and commercialization, paving the way for promising revenue opportunities. Expanding IP Portfolio Impact BioMedical’s ability to secure patents across jurisdictions underscores its commitment to innovation and its potential for market leadership. The company’s IP portfolio includes patents for insect repellent compositions and inflammatory disease treatments in the U.S., Canada, and other regions, providing a strong competitive edge. The Road Ahead As a relatively new public entity, Impact BioMedical has already demonstrated an ability to attract investor confidence, build a robust IP portfolio, and establish partnerships for product development. The company’s technologies address critical health challenges, offering significant market potential in both developed and emerging markets. Conclusion Impact BioMedical (NYSEAmerican: IBO) is emerging as a promising force in biotechnology. With its focus on innovative healthcare solutions, a strong leadership team, and a growing IP portfolio, the company could be well-positioned for long-term growth. Impact BioMedical’s strategic initiatives and commitment to innovation offer a compelling case for investors looking to tap into the potential of healthcare advancements. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

November 18, 2024 07:00 AM Eastern Standard Time

1 ... 4 5 6 7 8 ... 3770